Skip to main content

Dexcom company profile

  • DXCM · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$83.33+2.38%Close 13 Nov 2026 · Market value $30.72B

About Dexcom

Dexcom is a medical device company focused on designing, developing and commercializing continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health. Its products include the Dexcom G7 and G7 15 Day CGM systems, the Dexcom ONE+ system sold in Europe, and Stelo, an over-the-counter glucose biosensor launched in the United States. The company sells to patients, caregivers and clinicians through a direct sales organization in North America and certain international markets, supplemented by distributors, and reports that most of its revenue comes from the United States. It also operates in markets across North America, Africa, Asia Pacific, Europe, Latin America and the Middle East. Its main manufacturing facilities are in Mesa, Arizona and Penang, Malaysia.

A summary of the business section of the company's latest annual report, filed 12 Feb 2026.

Company facts

TickerDXCM · Nasdaq
SectorMedical devices
IndustryHealth Care Equipment
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1093557
Latest annual report10-K, filed 12 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Jacob LeachPresident, CEO, and Director · Director323K · < 1%Shares withheld for tax, 8 Nov 2026
Kevin SayerExecutive Chair · Director302K · < 1%Sale under a 10b5-1 plan, 20 Aug 2026
Steven AltmanDirector63.7K · < 1%Grant or award, 28 May 2026
Jereme SylvainEVP, COO &amp; CFO63.3K · < 1%Shares withheld for tax, 8 Nov 2026
Mark FolettaDirector56.9K · < 1%Sale under a 10b5-1 plan, 3 Aug 2026
Sadie SternEVP Chief People &amp; Culture Off56.8K · < 1%Shares withheld for tax, 8 Nov 2026
Richard CollinsDirector40.2K · < 1%Grant or award, 28 May 2026
Nicholas AugustinosDirector38.5K · < 1%Sale under a 10b5-1 plan, 15 Sep 2026
Michael BrownEVP Chief Legal Compliance Off38.2K · < 1%Shares withheld for tax, 8 Nov 2026
Bridgette HellerDirector26.0K · < 1%Sale under a 10b5-1 plan, 12 Aug 2026
Kyle MaladyDirector22.7K · < 1%Grant or award, 28 May 2026
Jon ColemanEVP, Chief Commercial Officer17.2K · < 1%Sale under a 10b5-1 plan, 4 Jun 2026
Rimma DriscollDirector10.4K · < 1%Grant or award, 28 May 2026
Dr. Euan AshleyDirector0 · < 1%Gift, 30 Oct 2026
Boehnlein Glenn SDirector—Grant or award, 10 Sep 2026
Osterloh Albert Frederick IVDirector—Grant or award, 28 May 2026
GALA RENEE DDirector—Grant or award, 28 May 2026
Dahut Karen MDirector—Gift, 8 May 2025
TOPOL ERICDirector—Gift, 8 May 2025
Dolan Matthew VincentEVP, Strategy & Corporate Dev—Open-market sale, 29 Jan 2025

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

DXCM in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.